Award supports preclinical research of Lario’s CaV2.3 calcium channel inhibitors as a novel disease-modifying approach for treatment of Parkinson's disease.
Jul 23 2024 Lario Therapeutics , a biopharmaceutical company developing first-in-class precision medicines for epileptic and neurological disorders, today announced it has been awarded a $6 million USD grant from The Michael J. Fox Foundation for Parkinson’s Research . The program is in collaboration with the Oxford Parkinson’s Disease Centre, which will also be delivering key science as part of the grant.
Parkinson’s disease is a progressive neurodegenerative disorder occurring when brain cells that make dopamine, which coordinates movement, stop working or die. Symptoms are lifelong and worsen over time, including motor dysfunction, such as tremors, slowness, stiffness, walking, and balance problems, as well as problems such as depression and memory problems. More than 10 million people worldwide are estimated to be living with Parkinson’s, with no current cure.
“This significant funding from The Michael J. Fox Foundation will aid the work out of our therapeutic pipeline and the work we have achieved so far in advancing research in the field. We would like to thank the MJFF team for their support,” added Henning Steinhagen, Ph.D., Co-Founder and CEO of Lario Therapeutics. “This grant will help drive our ambition to progress our Cav2.3 program swiftly towards the clinic, to provide a new, effective treatment option for people with Parkinson’s disease.
Therapeutics Biopharmaceutical Calcium Cell Neuroscience Pathology Ph Preclinical
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
'Hidden' sex differences in neurological reward pathways suggest opportunity for improved psychiatric therapeuticsA new study in the Journal of Neuroscience has discovered underlying sex differences in the molecular pathways that drive reward-related behaviors.
Read more »
Enzymatic RNA synthesis paves the way for sustainable therapeuticsWhile the COVID-19 vaccines introduced many people to RNA-based medicines, RNA oligonucleotides have already been on the market for years to treat diseases like Duchenne Muscular Dystrophy and amyloidosis.
Read more »
Innovative approaches in polymer nanoparticle synthesis for RNA therapeuticsRNA therapy with polymer nanoparticles is considered a promising approach for the treatment of various illnesses.
Read more »
Mason Greenwood: Marseille sign Man Utd forwardMarseille sign forward Mason Greenwood from Manchester United until 2029 in a deal worth up to 31.6m euros (£26.6m).
Read more »
Mason Greenwood: Marseille sign Man Utd forwardMarseille sign forward Mason Greenwood from Manchester United until 2029 in a deal worth up to 31.6m euros (£26.6m).
Read more »
Craig Wright admits he isn't the inventor of Bitcoin after High Court judgment in UKOzzie definitely not Satoshi Nakamoto, faces £6M legal bill and possible perjury trial
Read more »